John Foley, Regina Berkovich, Mark Gudesblatt, Elizabeth Luce, Beth Schneider, Carl de Moor, Shirley Liao, Lily Lee, Karthik Bodhinathan, Robin Avila
{"title":"在接受natalizumab或其他疗法治疗的多发性硬化症患者中描述“感觉良好的体验”。","authors":"John Foley, Regina Berkovich, Mark Gudesblatt, Elizabeth Luce, Beth Schneider, Carl de Moor, Shirley Liao, Lily Lee, Karthik Bodhinathan, Robin Avila","doi":"10.2217/nmt-2022-0003","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a 'feel-good experience' (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with natalizumab or other disease-modifying therapies (other-DMT). <b>Methods:</b> Questionnaire data from RRMS patients who use MyMSTeam, an online patient social network, were analyzed. <b>Results:</b> The survey included 347 patients (95 natalizumab; 252 other-DMT). More natalizumab than other-DMT patients self-reported having an FGE (62.1 vs 44.8%; p = 0.001) as well as other physical, emotional and cognitive benefits. <b>Conclusion:</b> This study demonstrates that physical, emotional and cognitive benefits were more commonly reported by patients treated with natalizumab than those treated with other disease-modifying therapies and helps characterize patient-reported factors associated with the FGE.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies.\",\"authors\":\"John Foley, Regina Berkovich, Mark Gudesblatt, Elizabeth Luce, Beth Schneider, Carl de Moor, Shirley Liao, Lily Lee, Karthik Bodhinathan, Robin Avila\",\"doi\":\"10.2217/nmt-2022-0003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> Patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a 'feel-good experience' (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with natalizumab or other disease-modifying therapies (other-DMT). <b>Methods:</b> Questionnaire data from RRMS patients who use MyMSTeam, an online patient social network, were analyzed. <b>Results:</b> The survey included 347 patients (95 natalizumab; 252 other-DMT). More natalizumab than other-DMT patients self-reported having an FGE (62.1 vs 44.8%; p = 0.001) as well as other physical, emotional and cognitive benefits. <b>Conclusion:</b> This study demonstrates that physical, emotional and cognitive benefits were more commonly reported by patients treated with natalizumab than those treated with other disease-modifying therapies and helps characterize patient-reported factors associated with the FGE.</p>\",\"PeriodicalId\":19114,\"journal\":{\"name\":\"Neurodegenerative disease management\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurodegenerative disease management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/nmt-2022-0003\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nmt-2022-0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 1
摘要
目的:接受natalizumab治疗的复发-缓解型多发性硬化症(RRMS)患者有一种“感觉良好的体验”(FGE)。作者使用接受natalizumab或其他疾病改善疗法(other- dmt)治疗的RRMS患者的调查数据来描述FGE。方法:对使用在线患者社交网络MyMSTeam的RRMS患者的问卷数据进行分析。结果:调查包括347例患者(95例natalizumab;252 other-DMT)。natalizumab比其他dmt患者自我报告的FGE更多(62.1 vs 44.8%;P = 0.001)，以及其他身体、情感和认知方面的益处。结论:本研究表明，接受natalizumab治疗的患者比接受其他疾病改善疗法治疗的患者更常报告身体、情绪和认知方面的益处，并有助于表征患者报告的与FGE相关的因素。
Characterizing the 'feel-good experience' in multiple sclerosis patients treated with natalizumab or other therapies.
Aim: Patients with relapsing-remitting multiple sclerosis (RRMS) treated with natalizumab have anecdotally reported a 'feel-good experience' (FGE). The authors characterized the FGE using survey data from patients with RRMS treated with natalizumab or other disease-modifying therapies (other-DMT). Methods: Questionnaire data from RRMS patients who use MyMSTeam, an online patient social network, were analyzed. Results: The survey included 347 patients (95 natalizumab; 252 other-DMT). More natalizumab than other-DMT patients self-reported having an FGE (62.1 vs 44.8%; p = 0.001) as well as other physical, emotional and cognitive benefits. Conclusion: This study demonstrates that physical, emotional and cognitive benefits were more commonly reported by patients treated with natalizumab than those treated with other disease-modifying therapies and helps characterize patient-reported factors associated with the FGE.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
